AGIOS PHARMACEUTICALS, INC. Selling, General and Administrative Expense
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Selling, General and Administrative Expense of $51.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $51.55M, a 12.38% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $48.30M, a 16.32% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $51.61M, a 0.17% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $41.27M, a 7.10% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $180.28M, a 14.99% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $156.78M, a 30.76% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $119.90M, a 1.45% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $121.67M, a 0.19% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $51.55M 10-Q · filed 2026-07-30 | $99.85M 10-Q · filed 2026-07-30 | $151.46M derived: sum of 3 quarters · filed 2026-07-30 | $192.74M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $48.30M 10-Q · filed 2026-04-29 | $99.91M derived: sum of 2 quarters · filed 2026-04-29 | $141.19M derived: sum of 3 quarters · filed 2026-04-29 | $187.06M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $51.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $92.88M derived: sum of 2 quarters · filed 2026-02-12 | $138.75M derived: sum of 3 quarters · filed 2026-07-30 | $180.28M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $41.27M 10-Q · filed 2025-10-30 | $87.14M derived: sum of 2 quarters · filed 2026-07-30 | $128.67M 10-Q · filed 2025-10-30 | $180.37M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $45.87M 10-Q · filed 2026-07-30 | $87.40M 10-Q · filed 2026-07-30 | $139.09M derived: sum of 3 quarters · filed 2026-07-30 | $177.63M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $41.53M 10-Q · filed 2026-04-29 | $93.22M derived: sum of 2 quarters · filed 2026-04-29 | $131.76M derived: sum of 3 quarters · filed 2026-04-29 | $167.30M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $51.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $90.23M derived: sum of 2 quarters · filed 2026-02-12 | $125.77M derived: sum of 3 quarters · filed 2026-02-12 | $156.78M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $38.54M 10-Q · filed 2025-10-30 | $74.07M derived: sum of 2 quarters · filed 2025-10-30 | $105.09M 10-Q · filed 2025-10-30 | $140.39M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $35.54M 10-Q · filed 2025-07-31 | $66.55M 10-Q · filed 2025-07-31 | $101.86M derived: sum of 3 quarters · filed 2026-02-12 | $127.68M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | $31.01M 10-Q · filed 2025-05-01 | $66.32M derived: sum of 2 quarters · filed 2026-02-12 | $92.14M derived: sum of 3 quarters · filed 2026-02-12 | $122.55M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | $35.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $61.13M derived: sum of 2 quarters · filed 2026-02-12 | $91.54M derived: sum of 3 quarters · filed 2026-02-12 | $119.90M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $25.82M 10-Q · filed 2024-10-31 | $56.23M derived: sum of 2 quarters · filed 2024-10-31 | $84.60M 10-Q · filed 2024-10-31 | $117.37M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | $30.41M 10-Q · filed 2024-08-01 | $58.78M 10-Q · filed 2024-08-01 | $91.55M derived: sum of 3 quarters · filed 2025-02-13 | $120.67M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | $28.37M 10-Q · filed 2024-05-02 | $61.14M derived: sum of 2 quarters · filed 2025-02-13 | $90.26M derived: sum of 3 quarters · filed 2025-02-13 | $118.53M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | $32.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $61.89M derived: sum of 2 quarters · filed 2025-02-13 | $90.16M derived: sum of 3 quarters · filed 2025-02-13 | $121.67M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $29.12M 10-Q · filed 2023-11-02 | $57.39M derived: sum of 2 quarters · filed 2023-11-02 | $88.90M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $28.26M 10-Q · filed 2023-08-03 | $59.78M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $31.52M 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $121.44M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $115.11M 10-K · filed 2023-02-23 | $149.07M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $102.01M 10-K · filed 2022-02-24 | $132.03M 10-K · filed 2020-02-19 | |||
| 2018-12-31 | $114.14M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $71.12M 10-K · filed 2020-02-19 | ||||
| 2016-12-31 | $50.71M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |